Rheumatoid Arthritis



Validation of the French Version of the Health Assessment Questionnaire II (HAQ-II) for Rheumatoid Arthritis


Condition:   Rheumatoid Arthritis
Intervention:  
Sponsor:   Rennes University Hospital
Completed


Anxiety Depression and Rheumatoid Arthritis


Condition:   Rheumatoid Arthritis
Intervention:   Other: Anxiety or depression
Sponsor:   Sichuan Provincial People's Hospital
Not yet recruiting


The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis


Condition:   RheumatoId Arthritis
Intervention:   Device: Hyperbaric Oxygen
Sponsor:   David Grant U.S. Air Force Medical Center
Enrolling by invitation


A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics


Condition:   Rheumatoid Arthritis
Interventions:   Drug: E6011;   Drug: Placebo
Sponsor:   Eisai Co., Ltd.
Recruiting


A Dose Response Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Methotrexate


Condition:   Rheumatoid Arthritis
Interventions:   Drug: E6011;   Drug: Placebo
Sponsor:   Eisai Co., Ltd.
Recruiting


Rheumatoid Arthritis Patients and Porphyromonas Gingivalis


Condition:   Rheumatoid Arthritis
Interventions:   Procedure: blood sample;   Procedure: synovial tissue
Sponsor:   Centre Hospitalier Universitaire de Saint Etienne
Recruiting


Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients


Condition:   Rheumatoid Arthritis
Interventions:   Biological: VAY736;   Biological: VAY736 placebo
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting


Oral Metagenomic Biomarkers in Rheumatoid Arthritis


Condition:   Rheumatoid Arthritis
Interventions:   Procedure: Dental Plaque;   Other: Multi-dimensional health assessment questionnaire (MDHAQ);   Other: Saliva Collection
Sponsors:   University of Florida;   United States Department of Defense;   VA Medical Center-Gainesville
Recruiting


Pragmatic Study Comparing the Clinical Evlauation Methods ( C) and / or Ultrasound Method ( B or D) in Rheumatoid Arthritis to Adapt Treatment


Condition:   Rheumatoid Arthritis
Interventions:   Device: Xrays;   Device: Ultrasound (B mode );   Device: Ultrasound (D mode)
Sponsor:   University Hospital, Brest
Recruiting


Reduced Ultrasound Counts in Rheumatoid Arthritis


Condition:   Rheumatoid Arthritis
Intervention:  
Sponsors:   Hospital General Universitario Gregorio Marañon;   Roche Pharma AG
Recruiting


Incorporation of Patient Reported Outcomes Data in the Care of US Veterans With Rheumatoid Arthritis


Condition:   Rheumatoid Arthritis
Interventions:   Other: PRO data utilized;   Other: PRO data not utilized
Sponsors:   North Florida Foundation for Research and Education;   Pfizer;   VA Office of Research and Development
Active, not recruiting


A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy


Condition:   Rheumatoid Arthritis
Interventions:   Drug: Humira (adalimumab);   Drug: SB5 (proposed biosimilar to adalimumab)
Sponsor:   Samsung Bioepis Co., Ltd.
Completed


Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients


Condition:   Rheumatoid Arthritis
Interventions:   Biological: CFZ533;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Completed


The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis


Condition:   Rheumatoid Arthritis
Interventions:   Dietary Supplement: Protein;   Dietary Supplement: Carbohydrate (Placebo);   Other: Resistance Exercise Program
Sponsors:   Johns Hopkins University;   National Institute on Aging (NIA);   American College of Rheumatology Research and Education Foundation
Suspended


Discovering the Antecedents of Rheumatoid Arthritis Flare


Condition:   Rheumatoid Arthritis
Intervention:  
Sponsor:   Rockefeller University
Recruiting


ACTH Gel Therapy in Rheumatoid Arthritis


Condition:   Rheumatoid Arthritis
Intervention:   Drug: ACTHAR gel
Sponsors:   Dr. Larry W. Moreland;   Mallinckrodt
Recruiting



Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis


Condition:   Rheumatoid Arthritis
Intervention:   Other: Braquial ecography
Sponsors:   Hospital Universitario de Canarias;   Roche Pharma AG
Active, not recruiting


Special Investigation in Patients With Rheumatoid Arthritis (Combo Study; Adalimumab With High Dose Methotrexate)


Condition:   Rheumatoid Arthritis
Intervention:  
Sponsor:   AbbVie (prior sponsor, Abbott)
Active, not recruiting


Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis


Condition:   Rheumatoid Arthritis
Interventions:   Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs);   Drug: Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs);   Biological: UC-MSC+DMARDS
Sponsor:   Alliancells Bioscience Corporation Limited
Unknown status


Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)


Condition:   Rheumatoid Arthritis
Intervention:  
Sponsor:   AbbVie (prior sponsor, Abbott)
Completed


The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)


Condition:   Rheumatoid Arthritis
Interventions:   Biological: apremilast;   Other: Placebo
Sponsor:   Baylor Research Institute
Completed


Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy


Condition:   Rheumatoid Arthritis
Intervention:   Drug: Remicade
Sponsors:   University of California, Los Angeles;   National Heart, Lung, and Blood Institute (NHLBI)
Completed


Prospective Study on Intensive Early Rheumatoid Arthritis Treatment


Condition:   Rheumatoid Arthritis
Interventions:   Drug: adalimumab, plus prednisone;   Drug: adalimumab plus placebo
Sponsor:   IRCCS Policlinico S. Matteo
Completed


A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.


Condition:   Rheumatoid Arthritis
Interventions:   Drug: Imatinib;   Drug: Methotrexate;   Drug: Imatinib Placebo
Sponsor:   Novartis Pharmaceuticals
Completed

Refine Your Search Advanced Search